Furthermore, the combination of anti-PD-1 monoclonal antibodies with anti-VEGF agents has emerged as a safe and effective strategy for the second-line or subsequent therapy of recurrent or metastatic HNSCC. This evidence concerns the gene VEGFA and head and neck squamous cell carcinoma.